NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (TASE: KMDA), an Israeli biopharmaceutical company, specializing in development, manufacturing and marketing of specialty plasma bio-therapeutics by intravenous or inhaled route for life saving uses is now reporting a new promise stemming from several pre clinical studies with its AAT product. These breaking news further support the scientific and clinical rationale behind Kamada’s already in-development AAT drug for diabetes indication as well as promote its possible entry to develop additional indications for this protein. Based on the results, Kamada reports that its AAT protein is modulating the activity of type B lymphocytes and by that enables the avoidance of organ transplant rejection and raises the likelihood for the transplant success.
